{"url_path":"/sec/fbrx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1419041/0001193125-26-215862-index.html","accession_number":"0001193125-26-215862","cik":"0001419041","ticker":"FBRX","issuer_name":"Forte Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1419041/0001193125-26-215862-index.html","primary_entity_key":"0001419041","primary_entity_name":"Forte Biosciences, Inc."},"word_count":336,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n10.1*^\n\n \n\n[Amended and Restated Non-Employee Director Compensation Policy.](fbrx-ex10.htm)\n\n \n\n \n\n \n\n31.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](fbrx-ex31_1.htm)\n\n \n\n \n\n \n\n31.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](fbrx-ex31_2.htm)\n\n \n\n \n\n \n\n32.1*±\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](fbrx-ex32_1.htm)\n\n \n\n \n\n \n\n32.2*±\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](fbrx-ex32_2.htm)\n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover page Interactive Data File (embedded with the Inline XBRL document)\n\n \n\n* Filed herewith.\n\n^ Indicates management contract or compensatory plan.\n\n± The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Forte Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.\n\n \n\n \n\n75\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nForte Biosciences, Inc.\n\n \n\n \n\n \n\nDate: May 11, 2026\n\nBy:\n\n \n\n/s/ Paul Wagner\n\n \n\n \n\n \n\nPaul Wagner, Ph.D.\n\n \n\n \n\n \n\nChief Executive Officer\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\nDate: May 11, 2026\n\nBy:\n\n \n\n/s/ Antony Riley\n\n \n\n \n\n \n\nAntony Riley\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial Officer)\n\n \n\n76"}